Gyre Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-21.6M | $-16.9M | $-14.8M | $-6.6M | $-10.0M | $-7.0M | $-8.5M | $10.9M |
| Depreciation & Amortization | $173.0K | $389.0K | $470.0K | $680.0K | $974.0K | $2.2M | $2.5M | $2.0M |
| Depreciation | $200.0K | $400.0K | $500.0K | $700.0K | $1.0M | $2.2M | $2.5M | $2.0M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $863.0K | $635.0K | $326.0K | $244.0K | $298.0K | $7.8M | $8.5M | $4.9M |
| Net Cash from Operating Activities | $-19.9M | $-18.5M | $-19.1M | $-6.4M | $-40.6M | $-64.2M | $-83.7M | $138.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $23.0K | $468.0K | $272.0K | $4.0K | $41.0K | $333.0K | $1.4M | $3.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-11.2M | — | — | — | $13.4M | $39.8M | $-57.7M | $-62.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $82.0K | — | — | — | — | — |
| Net Cash from Financing Activities | $21.1M | — | — | — | $-552.0K | $-626.0K | $82.8M | $6.4M |
| Net Change in Cash | $4.2M | $-18.8M | $27.6M | $-1.3M | $-573.0K | $-25.0M | $-58.6M | $81.9M |
| Free Cash Flow | $-20.0M | $-18.9M | $-19.4M | $-6.4M | $-40.7M | $-64.6M | $-85.1M | $135.0M |